USANA Health Sciences Files 8-K on Financials

Ticker: USNA · Form: 8-K · Filed: 2025-10-22T00:00:00.000Z

Sentiment: neutral

Topics: financial-reporting, operations

Related Tickers: USNA

TL;DR

USANA filed an 8-K on Oct 22, 2025, detailing financial results and operations.

AI Summary

USANA Health Sciences, Inc. filed an 8-K on October 22, 2025, reporting on its results of operations and financial condition. The filing also included Regulation FD disclosures and financial statements and exhibits. The company is incorporated in Utah and its fiscal year ends on December 28.

Why It Matters

This 8-K filing provides investors with crucial updates on USANA Health Sciences' financial performance and operational status, impacting investment decisions.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.

Key Players & Entities

USANA HEALTH SCIENCES INC (company) — Registrant
October 22, 2025 (date) — Date of Report
Utah (location) — State of Incorporation
8019547100 (phone_number) — Business Phone

FAQ

What is the primary purpose of this Form 8-K filing?

The primary purpose of this Form 8-K filing is to report on the Results of Operations and Financial Condition of USANA Health Sciences, Inc., along with Regulation FD Disclosures and Financial Statements and Exhibits.

When was this Form 8-K filed?

This Form 8-K was filed on October 22, 2025.

In which state is USANA Health Sciences, Inc. incorporated?

USANA Health Sciences, Inc. is incorporated in Utah.

What is the fiscal year end for USANA Health Sciences, Inc.?

The fiscal year end for USANA Health Sciences, Inc. is December 28.

What is the principal executive office address for USANA Health Sciences, Inc.?

The principal executive office address is 3838 West Parkway Boulevard, Salt Lake City, Utah 84120.

From the Filing

0000896264-25-000213.txt : 20251022 0000896264-25-000213.hdr.sgml : 20251022 20251022161242 ACCESSION NUMBER: 0000896264-25-000213 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20251022 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20251022 DATE AS OF CHANGE: 20251022 FILER: COMPANY DATA: COMPANY CONFORMED NAME: USANA HEALTH SCIENCES INC CENTRAL INDEX KEY: 0000896264 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences EIN: 870500306 STATE OF INCORPORATION: UT FISCAL YEAR END: 1228 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35024 FILM NUMBER: 251410262 BUSINESS ADDRESS: STREET 1: 3838 WEST PARKWAY BLVD. CITY: SALT LAKE CITY STATE: UT ZIP: 84120-6336 BUSINESS PHONE: 8019547100 MAIL ADDRESS: STREET 1: 3838 WEST PARKWAY BLVD. STREET 2: 3838 WEST PARKWAY BLVD. CITY: SALT LAKE CITY STATE: UT ZIP: 84120-6336 FORMER COMPANY: FORMER CONFORMED NAME: USANA INC DATE OF NAME CHANGE: 19930125 8-K 1 usna-20251022.htm 8-K usna-20251022 FALSE 0000896264 0000896264 2025-10-22 2025-10-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________________ FORM 8-K _____________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 22, 2025 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commission File No.) (IRS Employer Identification No.) 3838 West Parkway Boulevard Salt Lake City , Utah 84120 (Address of principal executive offices, Zip Code) Registrant's telephone number, including area code: ( 801 ) 954-7100 Check the appropriate box below if the Form 8-K ﬁling is intended to simultaneously satisfy the ﬁling obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share USNA New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o Item 2.02    Results of Operations and Financial Condition. On October 22, 2025, USANA Health Sciences, Inc. (the “Company” or “USANA”) issued a press release announcing its financial results for the third quarter ended September 27, 2025. The release also announced that the Company will post a document titled “Management Commentary” on the Company’s website and that executives of the Company will hold a conference call with investors, to be broadcast over the World Wide Web and by telephone and provided access information, date and time for the conference call. The Company noted that the call will consist of brief remarks by the Company’s management team, before moving directly into questi